European consensus for the diagnosis of MCI and mild dementia: Preparatory phase.

Humans Cognitive Dysfunction / diagnosis Consensus Sensitivity and Specificity Dementia / diagnosis Biomarkers
Delphi procedure MCI consensus etiological diagnosis imaging major neurocognitive disorder mild dementia - biomarker neurocognitive disorders

Journal

Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978

Informations de publication

Date de publication:
05 2023
Historique:
revised: 29 07 2022
received: 02 03 2022
accepted: 09 08 2022
medline: 15 5 2023
pubmed: 10 10 2022
entrez: 9 10 2022
Statut: ppublish

Résumé

Etiological diagnosis of neurocognitive disorders of middle-old age relies on biomarkers, although evidence for their rational use is incomplete. A European task force is defining a diagnostic workflow where expert experience fills evidence gaps for biomarker validity and prioritization. We report methodology and preliminary results. Using a Delphi consensus method supported by a systematic literature review, 22 delegates from 11 relevant scientific societies defined workflow assumptions. We extracted diagnostic accuracy figures from literature on the use of biomarkers in the diagnosis of main forms of neurocognitive disorders. Supported by this evidence, panelists defined clinical setting (specialist outpatient service), application stage (MCI-mild dementia), and detailed pre-assessment screening (clinical-neuropsychological evaluations, brain imaging, and blood tests). The Delphi consensus on these assumptions set the stage for the development of the first pan-European workflow for biomarkers' use in the etiological diagnosis of middle-old age neurocognitive disorders at MCI-mild dementia stages. Rational use of biomarkers in neurocognitive disorders lacks consensus in Europe. A consensus of experts will define a workflow for the rational use of biomarkers. The diagnostic workflow will be patient-centered and based on clinical presentation. The workflow will be updated as new evidence accrues.

Identifiants

DOI: 10.1002/alz.12798 PMID: 36209379
pubmed: 36209379
doi: 10.1002/alz.12798
doi:

Substances chimiques

Biomarkers 0

Types de publication

Systematic Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1729-1741

Informations de copyright

© 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Références

Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614-629. https://doi.org/10.1016/S1474-4422(14)70090-0
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia. 2011;7(3):263-269. Portico. https://doi.org/10.1016/j.jalz.2011.03.005
McKeith IG, Ferman TJ, Thomas AJ, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94:743-755. https://doi.org/10.1212/WNL.0000000000009323
Nobili F, Arbizu J, Bouwman F, et al. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. E J Neurol. 2018;25:1201-1217. https://doi.org/10.1111/ene.13728
Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535-562. https://doi.org/10.1016/j.jalz.2018.02.018
Schöll M, Maass A, Mattsson N, et al. Biomarkers for tau pathology. Mol Cell Neurosci. 2019;97:18-33. https://doi.org/10.1016/j.mcn.2018.12.001
Wolters EE, Dodich A, Boccardi M, et al. Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework. Eur J Nucl Med Mol Imaging. 2021;48:2097-2109. https://doi.org/10.1007/s00259-020-05118-w
Kägi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010;81:5-12. https://doi.org/10.1136/jnnp.2008.157370
Yoshita M, Taki J, Yokoyama K, et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology. 2006;66:1850-1854. https://doi.org/10.1212/01.wnl.0000219640.59984.a7
Rascol O, Schelosky L. 123 I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders. Mov Disord. 2009;24:S732-41. https://doi.org/10.1002/mds.22499
Boeve BF, Silber MH, Ferman TJ, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 2013;14:754-762. https://doi.org/10.1016/j.sleep.2012.10.015
Frisoni GB, Boccardi M, Barkhof F, et al. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurol. 2017;16:661-676. https://doi.org/10.1016/S1474-4422(17)30159-X
Boccardi M, Nicolosi V, Festari C, et al. Italian consensus recommendations for a biomarker-based aetiological diagnosis in mild cognitive impairment patients. E J Neurol. 2020;27:475-483. https://doi.org/10.1111/ene.14117
de Mendonça A, Ribeiro F, Guerreiro M, Garcia C. Frontotemporal mild cognitive impairment. J Alzheimers Dis. 2004;6:1-9. https://doi.org/10.3233/jad-2004-6101
Taragano FE ARF. Mild behavioral impairment: the early diagnosis. The Eleventh International Congress of the International Psychogeriatric Association. Chicago, Illinois: 2003, p. 17-22.
Wright Rowe. Principles of Forecasting: A Handbook of Researchers and Practitioners, Boston. In: J. Scott Armstrong, ed. Kluwer Academic Publishers; 2001.
McLaughlin MW. The rand change agent study revisited: macro perspectives and micro realities. Educ Res. 1990;19:11-16. https://doi.org/10.3102/0013189x019009011
Rowe G, Wright G. The Delphi technique as a forecasting tool: issues and analysis. Int J Forecast. 1999;15:353-375. https://doi.org/10.1016/S0169-2070(99)00018-7
Dalkey N, Helmer O. An experimental application of the DELPHI method to the use of experts. Manag Sci. 1963;9:458-467. https://doi.org/10.1287/mnsc.9.3.458
Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000;32:1008-1015.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006-1012. https://doi.org/10.1016/j.jclinepi.2009.06.005
Stinton C, McKeith I, Taylor J-P, et al. Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry. 2015;172:731-742. https://doi.org/10.1176/appi.ajp.2015.14121582
Whiting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529-536. https://doi.org/10.7326/0003-4819-155-8-201110180-00009
Boccardi M, Festari C, Altomare D, et al. Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. Eur J Nucl Med Mol Imaging. 2018;45:1470-1486. https://doi.org/10.1007/s00259-018-4024-1
Hampel H, Cummings J, Blennow K, Gao P, Jack CR Jr, Vergallo A. Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol. 2021;17(9):580-589. https://doi.org/10.1038/s41582-021-00520-w. Epub 2021 Jul 8.
Markmann C, Spickermann A, von der Gracht HA, Brem A. Improving the question formulation in Delphi-like surveys: analysis of the effects of abstract language and amount of information on response behavior. Futures Foresight Sci. 2021;3:e56-76. https://doi.org/10.1002/ffo2.56
Mauksch S, von der Gracht HA, Gordon TJ. Who is an expert for foresight? A review of identification methods. Technol Forecast Soc Change. 2020;154:119982. https://doi.org/10.1016/j.techfore.2020.119982
Delphi method n.d. https://en.wikipedia.org/wiki/Delphi_method (accessed June 22, 2021)
Keeney S, Hasson F, McKenna H. The Delphi Technique in Nursing and Health Research. Wiley; 2011. https://doi.org/10.1002/9781444392029
Helmer-Hirschberg O. Analysis of the Future: The Delphi Method. RAND Corporation; 1697.
Mullen PM. Delphi: myths and reality. J Health Organ Manag. 2003;17:37-52. https://doi.org/10.1108/14777260310469319
Grisham T. The Delphi technique: a method for testing complex and multifaceted topics. Int J Manag Proj Bus. 2009;2:112-130. https://doi.org/10.1108/17538370910930545
Akins RB, Tolson H, Cole BR. Stability of response characteristics of a Delphi panel: application of bootstrap data expansion. BMC Med Res Methodol. 2005;5:37. https://doi.org/10.1186/1471-2288-5-37
Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Aducanumab: appropriate use recommendations. J Prev Alzheimers Dis. 2021:8(4):398-410. https://doi.org/10.14283/jpad.2021.41
Yiannopoulou KG, Anastasiou AI, Zachariou V, Pelidou S-H. Reasons for failed trials of disease-modifying treatments for Alzheimer Disease and their contribution in recent research. Biomedicines. 2019;7:97-113. https://doi.org/10.3390/biomedicines7040097
Elson P. Do older adults presenting with memory complaints wish to be told if later diagnosed with Alzheimer's disease? Int J Geriatr Psychiatry. 2006;21:419-425. https://doi.org/10.1002/gps.1485
Brodaty H, Seeher K, Gibson L. Dementia time to death: a systematic literature review on survival time and years of life lost in people with dementia. Int Psychogeriatr. 2012;24:1034-1045. https://doi.org/10.1017/S1041610211002924
Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007;15:84-87. https://doi.org/10.1097/01.JGP.0000231744.69631.33
Armstrong MJ, Weintraub D. The case for antipsychotics in dementia with Lewy bodies. Mov Disord Clin Pract. 2017;4:32-35. https://doi.org/10.1002/mdc3.12383
Chételat G, Arbizu J, Barthel H, et al. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurol. 2020;19:951-962. https://doi.org/10.1016/S1474-4422(20)30314-8

Auteurs

Cristina Festari (C)

Laboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.

Federico Massa (F)

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy.

Matteo Cotta Ramusino (M)

Unit of Behavioral Neurology, IRCCS Mondino Foundation, Pavia, Italy.
Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.

Federica Gandolfo (F)

Department of Geriatric Care, Orthogeriatrics and Rehabilitation, E.O. Galliera Hospital, Genova, Italy.

Valentina Nicolosi (V)

UOC Neurologia, Ospedale Magalini (ULSS 9 - Veneto), Villafranca di Verona (VR), Italy.

Stefania Orini (S)

Alzheimer's Unit - Memory Clinic, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Dipartimento di Scienze Cliniche e Sperimentali, Università degli Studi di Brescia, Brescia, Italy.

Dag Aarsland (D)

Department of Old Age Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Centre for Age-Related Diseases, Stavanger University Hospital, Stavanger, Norway.
European DLB Consortium.

Federica Agosta (F)

Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Vita-Salute San Raffaele University, Milan, Italy.
European Academy of Neurology.

Claudio Babiloni (C)

Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome, Italy.
Hospital San Raffaele of Cassino, Cassino (FR), Italy.
Europe, Middle East and Africa Chapter of the International Federation of Clinical Neurophysiology.

Mercè Boada (M)

Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Barbara Borroni (B)

Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Neurology Unit, Department of Neurological and Vision Sciences, ASST Spedali Civili, Brescia, Italy.
European FTLD network.

Stefano Cappa (S)

Dementia Research Center, IRCCS Mondino Foundation, Pavia, Italy.
Scuola Universitaria Superiore IUSS Pavia, Pavia, Italy.
Federation of the European Societies of Neuropsychology.

Bruno Dubois (B)

Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A), ICM, Salpetriere Hospital, AP-HP, University Paris 6, Paris, France.

Kristian S Frederiksen (KS)

European Academy of Neurology.
Danish Dementia Research Centre, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Lutz Froelich (L)

Department of Geriatric Psychiatry, Central Institute of Mental Health Mannheim, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany.
European Alzheimer Disease Consortium.

Valentina Garibotto (V)

NIMTLab, Faculty of Medicine, University of Geneva, Switzerland.
Division of Nuclear Medicine and Molecular Imaging, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland.
Center for Biomedical Imaging, CIBM, Geneva, Switzerland.
European Association of Nuclear Medicine.

Jean Georges (J)

Alzheimer Europe.

Alexander Haliassos (A)

ESEAP-Proficiency Testing Scheme for Clinical Laboratories, Athens, Greece.
International Federation of Clinical Chemistry.

Oskar Hansson (O)

Department of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, Lund, Sweden.
Memory Clinic, Skåne University Hospital, Malmo, Sweden.

Frank Jessen (F)

European Alzheimer Disease Consortium.
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Department of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany.
Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.

Anita Kamondi (A)

Europe, Middle East and Africa Chapter of the International Federation of Clinical Neurophysiology.
Department of Neurology, National Institute of Mental Health, Neurology and Neurosurgery, Budapest, Hungary.

Roy P C Kessels (RPC)

Federation of the European Societies of Neuropsychology.
Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, The Netherlands.
Vincent van Gogh Institute for Psychiatry, Venray, The Netherlands.
Department of Medical Psychology and Radboudumc Alzheimer Center, Radboud University Medical Center, Nijmegen, The Netherlands.

Silvia Morbelli (S)

IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Dept of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.

John T O'Brien (JT)

European DLB Consortium.
Department of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, UK.

Markus Otto (M)

European FTLD network.
Department of Neurology, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.

Armand Perret-Liaudet (A)

International Federation of Clinical Chemistry.
Laboratory of Neurobiology, Department of Biochemistry and Molecular Biology, Hospices civils de Lyon; Research and Resources Memory Centre, Lyon, France.
BioRan Team, Centre de Recherche en Neurosciences de Lyon, CNRS UMR5292, INSERM U1028, Lyon, France.

Francesca B Pizzini (FB)

Verona University Hospital, Verona University, Dept. of Diagnostic and Public Health, Verona, Italy.
European Union of Medical Specialists.

Craig W Ritchie (CW)

Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
Brain Health Scotland, Edinburgh, UK.

Philip Scheltens (P)

Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.

Mathieu Vandenbulcke (M)

Neuropsychiatry, Leuven Brain Institute, KU Leuven, Leuven, Belgium.
Geriatric Psychiatry, University Psychiatric Centre KU Leuven, Leuven, Belgium.
European Association of Geriatric Psychiatry.

Ritva Vanninen (R)

European Union of Medical Specialists.
University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.

Frans Verhey (F)

European Association of Geriatric Psychiatry.
Department of Psychiatry and Neuropsychology/Alzheimer Centre Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.

Meike W Vernooij (MW)

Department of Radiology & Nuclear Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Department of Epidemiology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
European Society of Neuroradiology.

Tarek Yousry (T)

European Society of Neuroradiology.
Lysholm Department of Neuroradiology and the Neuroradiological Academic Unit, Department of Brain Repair and Rehabilitation, University College London Hospitals NHS Foundation Trust National Hospital for Neurology and Neurosurgery, London, UK.

Wiesje M Van Der Flier (WM)

Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.

Flavio Nobili (F)

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy.
IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Giovanni B Frisoni (GB)

Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland.
Geneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › European consensus for the diagnosis of MCI...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Troubles de la cognition › Dysfonctionnement cognitif › European consensus for the diagnosis of MCI...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Pensée (activité mentale) › Prise de décision › Consensus › European consensus for the diagnosis of MCI...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Sensibilité et spécificité › European consensus for the diagnosis of MCI...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › European consensus for the diagnosis of MCI...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › European consensus for the diagnosis of MCI...